Healthcare Sales & Marketing Network News: Irinotecan

Searching News Database: Irinotecan

HSMN NewsFeed - 16 Sep 2021
LUMAKRAS(TM) (Sotorasib) Combined With Vectibix(R) (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Jul 2021
Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 28 May 2020
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Feb 2019
FDA Approves Taiho Oncology's LONSURF(R) (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 10 Oct 2018
OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Submission of Investigational New Drug Application to Evaluate Tedopi(R) in Combination with Nivolumab in Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 7 Aug 2018
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI(TM) in combination with MEKTOVI(R) and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Jun 2018
PharmaEngine Announces Positive Topline Results from Global Pivotal Trial of PEP503 (NBTXR3) in Soft Tissue Sarcoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Nov 2017
Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Sep 2017
Oncolytics Biotech(R) Announces the Presentation of REOLYSIN(R) Clinical Data at ESMO 2017 Congress
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2017
Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA(R) (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Jan 2017
Merrimack Names Richard Peters, M.D., Ph.D., as President and CEO
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 9 Jan 2017
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 18 Nov 2016
Athenex and Lilly Enter Clinical Collaboration Agreement
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Oct 2016
Shire Granted EU Marketing Authorization of Onivyde(R), in Combination With 5-Fluorouracil (5-FU) and Leucovorin (LV),for the Treatment of Metastatic Adenocarcinoma of the Pancreas in Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 25 Jul 2016
ONIVYDE(R) Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas Who Have Progressed Following Gemcitabine Based Therapy
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 6 Jul 2016
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 6 Jun 2016
Celator Pharmaceuticals(R) Presented Phase 3 Trial Results in Patients with High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS(TM) (CPX-351) Significantly Improved Overall Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2016
Jazz Pharmaceuticals And Celator Pharmaceuticals Announce Agreement For Jazz Pharmaceuticals To Acquire Celator For $30.25 Per Share
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 25 Apr 2016
Celator(R) Pharmaceuticals Announces Positive Results Demonstrating Reduced Healthcare Resource Use with VYXEOS(TM) Compared to Standard Treatment for Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Apr 2016
Taiho's TAS-102 Meets Primary Endpoint of Improving Overall Survival in Phase III TERRA Study in Asian Patients with Refractory Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Mar 2016
Merrimack Announces Inclusion of ONIVYDE(R) (irinotecan liposome injection) as a Category 1 Treatment Option in the 2016 NCCN Guidelines for Pancreatic Adenocarcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Feb 2016
CHMP Issues Positive Opinion for LONSURF(R) (trifluridine/tipiracil) for Refractory Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 25 Jan 2016
Athenex Announces US FDA Allowance of the Investigation New Drug Application of Oradoxel, the Proprietary Oral Form of Docetaxel
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Jan 2016
Cellceutix Releases Data Used in Receiving FDA Orphan Drug Designation of Kevetrin for Pancreatic Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Oct 2015
Merrimack Announces U.S. FDA Approval of ONIVYDE(TM) (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Aug 2015
Celator(R) Pharmaceuticals Appoints Michael R. Dougherty as Executive Chairman of Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 6 Aug 2015
Merrimack Pharmaceuticals Names Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development
Biopharmaceuticals Drug Delivery Oncology Personnel

HSMN NewsFeed - 6 Apr 2015
European Commission Approves Amgen's Vectibix(R) (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 13 Oct 2014
FDA Approves AKYNZEO(R) (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)
Biopharmaceuticals FDA

HSMN NewsFeed - 3 Sep 2014
Celator(R) Pharmaceuticals Announces Appointment of Michael Dougherty as Chairman of the Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 14 Aug 2014
FDA Approves Genentech�s Avastin Plus Chemotherapy for Treatment of Advanced Cervical Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Jul 2014
FDA Grants Genentech�s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Jul 2014
FDA Grants Genentech�s Avastin Priority Review for Certain Types of Cervical Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 May 2014
Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 May 2014
Merrimack Pharmaceuticals Announces MM-398 Achieves Primary Endpoint of Overall Survival in Phase 3 Trial in Post-Gemcitabine Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Feb 2014
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Colorectal Cancer after Resection of Liver Metastases
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Dec 2013
European Commission Approves Update of Erbitux Metastatic Colorectal Cancer Labeling to Patients With RAS Wild-Type Tumors
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 Dec 2013
Celator(R) Pharmaceuticals Appoints Joseph M. Lobacki to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 28 Oct 2013
Lorus Therapeutics Appoints New Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 17 Oct 2013
Health Canada Approves A New Treatment Option For Patients With Gastrointestinal Stromal Tumours (GIST), A Rare Form Of Sarcoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 30 Aug 2013
Bayer's Stivarga(R) (regorafenib) Tablets Approved in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 Jul 2013
Celator(R) Pharmaceuticals Appoints Michael R. Dougherty to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 15 May 2013
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Feb 2013
Alchemia Appoints Charles Walker as Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Feb 2013
ZALTRAP(R) (ziv-aflibercept) Approved in the EU for Patients with Previously Treated Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 7 Jan 2013
Celator(R) Pharmaceuticals Announces Appointment of Lisa DeLuca as Vice President, Regulatory Affairs
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 18 Dec 2012
Celator(R) Pharmaceuticals Announces Appointment of Fred Powell as Chief Financial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 29 Oct 2012
Bayer's Stivarga(R) (regorafenib) Tablets New Drug Application Granted Priority Review by U.S. FDA for the Treatment of Patients with Gastrointestinal Stromal Tumors
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Sep 2012
Bayer's Stivarga(R) (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 10 Aug 2012
Genentech Study Showed That Adding Avastin to Radiation and Chemotherapy Significantly Extended the Time People with an Aggressive Form of Brain Cancer Lived without Their Disease Worsening
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Apr 2012
Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP(R) (aflibercept)
Biopharmaceuticals

HSMN NewsFeed - 14 Mar 2012
Everist Genomics Develops World's First Comprehensive Companion Diagnostics and Prognostics Portfolio for Early Diagnosis and Improved Treatment of Colorectal Cancer
Diagnostics Personalized Medicine Oncology

HSMN NewsFeed - 12 Oct 2011
Onyx Pharmaceuticals and Bayer Healthcare Restructure Global Oncology Partnership
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Jun 2011
ZALTRAP (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Mar 2011
APP Pharmaceuticals Issues a Nationwide Voluntary Recall of Irinotecan Hydrochloride Injection
Biopharmaceuticals Oncology Product Recall

HSMN NewsFeed - 18 Mar 2011
Amgen Statement on CHMP Opinion on Vectibix(R) (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 10 Mar 2011
Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Feb 2011
Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Feb 2011
FDA Approves Labeling Update for REYATAZ(R) (atazanavir sulfate) Capsules to Include Data Supporting the Recommended Adult Dose of REYATAZ/ritonavir 300/100 mg for HIV-1 Infected Pregnant Women
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 10 Jan 2011
Celator(R) Pharmaceuticals and Cephalon, Inc. Agree to Extend Research Agreement into Next Phase of Development
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Jan 2011
TetraLogic Closes $23 Million Second Tranche of Series C Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 7 Sep 2010
Pharmaceutical Industry Veteran Dr. Craig Eagle Appointed as an Independent Member to Regenicin Board of Directors
Regenerative Medicine Personnel

HSMN NewsFeed - 1 Sep 2010
Celator(R) Pharmaceuticals Raises $20 Million in Series D Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 29 Jul 2010
Calistoga Pharmaceuticals Appoints Langdon L. Miller, M.D., Executive Vice President, Research & Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Apr 2010
Aeterna Zentaris Announces Initiation of Phase 3 Registration Trial with Perifosine in Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Apr 2010
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 Mar 2010
Merck Serono: Erbitux Granted Extended Use in Japan for 1st-Line Treatment of mCRC Patients with KRAS Wild-Type Tumors
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Jan 2010
Amgen Presents Complete Results From Two Pivotal Phase 3 Studies of Vectibix(R) at Gastrointestinal Cancers Symposium
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Dec 2009
Dennis Winger Joins Nektar Therapeutics' Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Nov 2009
Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Sep 2009
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Sep 2009
Data Presented from Two Phase 3 ERBITUX(R) Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Sep 2009
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Jul 2009
ImClone Systems and Bristol-Myers Squibb Announce Revisions to ERBITUX(R) (cetuximab) U.S. Product Labeling for Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 Jun 2009
Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Jun 2009
Randomized Controlled Trial of Radioactive Resin Microspheres Demonstrates Significant Delay in Progression of Disease in Patients with Colorectal Cancer Liver Metastases who have Exhausted Chemotherapy
Biopharmaceuticals Oncology Gastroenterology

HSMN NewsFeed - 1 Jun 2009
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 May 2009
FDA Grants Accelerated Approval of Avastin for Brain Cancer (Glioblastoma) That Has Progressed Following Prior Therapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Mar 2009
ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX(R) in U.S.
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Jan 2009
ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplemental Biologics Application Submission for ERBITUX(R)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 3 Nov 2008
Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Oct 2008
ImClone Announces ERBITUX(R) Commercial Launch in Canada for Advanced Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Oct 2008
Study Published in New England Journal of Medicine Shows K-ras Gene Mutation Status May Affect Response to ERBITUX(R) Treatment
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Oct 2008
Pfizer Names New Head of Clinical Development and Medical Affairs for Its Oncology Business Unit
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 6 Oct 2008
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 19 Sep 2008
ERBITUX(R) Now Available in Japan for Use in Treating Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Sep 2008
ImClone Provides Update on Pivotal Phase 3 CRYSTAL Study in First-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Sep 2008
ImClone Submits Supplemental Biologics License Application for ERBITUX(R) in First-Line Head and Neck Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Aug 2008
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Aug 2008
CASTLE Data Showed Boosted REYATAZ(R) (atazanavir sulfate) and Lopinavir/r Achieved Similar Results for Undetectable Viral Load in Treatment-Naive HIV-1 Infected Patients, Regardless of Gender
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 31 Jul 2008
Bristol-Myers Squibb Proposes to Acquire ImClone Systems for $60.00 Per Share in Cash
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 28 Jul 2008
Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 16 Jul 2008
ERBITUX(R) (Cetuximab) Receives Approval in Japan for Use in Advanced Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Jul 2008
ImClone Announces Changes in Commercial Organization Leadership
Biopharmaceuticals Personnel

HSMN NewsFeed - 2 Jun 2008
ImClone Appoints Dr. Bernhard Ehmer Senior Vice President and Managing Director, International Operations
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Jun 2008
New Analyses of Pivotal Phase 3 Study of ERBITUX(R) Demonstrate Enhanced Efficacy in First-Line Metastatic Colorectal Cancer Patients with Wild-Type K-Ras Biomarker
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2008
Updated Data from Ongoing Phase 3 Trials Support the Continued Study of Vectibix(R) (panitumumab) in Combination with Standard Chemotherapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
Data Confirm Avastin(R) Helps Patients With Metastatic Colorectal Cancer Live Even Longer
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 May 2008
Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 May 2008
Sonus Pharmaceuticals and OncoGenex Technologies to Merge
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 16 May 2008
ERBITUX(R) (cetuximab) Data Demonstrate Improvements in Response Rate and Progression-Free Survival in Wild Type K-Ras Metastatic Colorectal Cancer Patients in First-Line Setting
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 May 2008
Celator(R) Pharmaceuticals Announces Appointment of Scott Jackson as CEO
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Mar 2008
Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Mar 2008
FDA Gives Go Ahead for Actavis' Irinotecan Hydrochloride Injection
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 3 Mar 2008
Pro-Pharmaceuticals DAVANAT(R) Extends Median Survival 6.7 Months for End-Stage Colorectal Cancer Patients After All Other Treatments Failed
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Feb 2008
Teva Announces Approval of Generic Camptosar(R)
Biopharmaceuticals Generics Oncology FDA

HSMN NewsFeed - 27 Feb 2008
APP Pharmaceuticals Receives Final Approval for Irinotecan Hydrochloride Injection
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 27 Feb 2008
Hospira Launches Generic Irinotecan Injection
Biopharmaceuticals Oncology Generics

HSMN NewsFeed - 12 Feb 2008
Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
Biopharmaceuticals

HSMN NewsFeed - 11 Feb 2008
New Data Shows DAVANAT(R) Extends Survival of End-Stage Colorectal Cancer Patients More Than 6 Months
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Feb 2008
CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 4 Feb 2008
Amgen and Takeda Announce Exclusive Collaboration in Japan on up to 13 Amgen Clinical Candidates
Biopharmaceuticals Licensing

HSMN NewsFeed - 24 Jan 2008
KRAS Gene Status May Impact Vectibix(TM) (Panitumumab) Efficacy and Patient Reported Outcomes in Advanced Colorectal Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Dec 2007
Vectibix(R) Approved in the European Union for the Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 Nov 2007
Published Data Suggest That ERBITUX(R) Enables Complete Surgical Resection of Colorectal Liver Metastases in Patients Previously Refractory to Conventional Systemic Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Nov 2007
Avastin Shows Encouraging Results in Phase II Study in Patients With the Most Aggressive Form of Brain Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Nov 2007
New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Oct 2007
Nektar Therapeutics Issues Statement on Exubera
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 17 Oct 2007
ImClone and Bristol-Myers Squibb Announce Joint Agreement with Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Oct 2007
APP Receives Tentative FDA Approval for Irinotecan Hydrochloride Injection, 20 mg/mL Packaged in 2 mL and 5 mL Single-Use Vials
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 2 Oct 2007
Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 25 Sep 2007
New Biomarker Data Links KRAS Gene to Vectibix(TM) Clinical Response
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Sep 2007
Pro-Pharmaceuticals Names Theodore Zucconi, Ph.D., President; Nominated to the Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Sep 2007
Vectibix(TM) (panitumumab) Receives Positive Opinion for Marketing Authorization in the European Union
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Sep 2007
ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Sep 2007
ImClone Settles Patent Lawsuit and Gains Rights to Additional Intellectual Property
Biopharmaceuticals Oncology Litigation Licensing

HSMN NewsFeed - 27 Jul 2007
Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Jul 2007
Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Jul 2007
Pro-Pharmaceuticals Updates Progress of Clinical Trials & DAVANAT(R) 505 (b)(2) Filings
Biopharmaceuticals Oncology Drug Delivery

HSMN NewsFeed - 28 Jun 2007
Pfizer Initiates Phase III Trial to Study Sunitinib Malate in Patients with Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Jun 2007
GPC Biotech Announces Partnering Agreement for Satraplatin for Japan with Yakult
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 18 Jun 2007
Health Canada approves new chemotherapy treatment for patients with metastatic colorectal cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Jun 2007
FDA Accepts and Grants Priority Review of ERBITUX(R) (Cetuximab) sBLA for Overall Survival in Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Jun 2007
Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Eloxatin(R) (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
The Eloxatin(R)-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
YM BioSciences Cleared to Initiate Clinical trial of Nimotuzumab in Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
FOLFOX4 (Eloxatin(R)-based Chemotherapy) After Surgery Improves Overall Survival in Patients With Early (Stage III) Colon Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 May 2007
Positive Final Data from HyCAMP(TM) Phase II Trial in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 May 2007
Amgen to Appeal CHMP Opinion on Vectibix(TM) (Panitumumab)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 May 2007
Nektar Announces New Organizational Structure and Spending Reduction Initiatives to Solidify the Company's Leadership Position in PEGylation and Pulmonary Drug Development
Biopharmaceuticals

HSMN NewsFeed - 30 Apr 2007
Enzon Receives FDA Clearance of Its Recently Filed PEG-SN38 IND Application
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Apr 2007
Pro-Pharmaceuticals Issues Corporate Update
Biopharmaceuticals

HSMN NewsFeed - 16 Apr 2007
Randomized Phase III Trial Showed ERBITUX Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Apr 2007
Pro-Pharmaceuticals Plans to Submit a New Drug Application for DAVANAT(R), as a Functional Excipient, with 5-FU to Treat Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Apr 2007
Pro-Pharmaceuticals Receives Letter from the FDA for New Drug Application for DAVANAT(R)/ 5-FU
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 10 Apr 2007
Data Available from ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Apr 2007
Innovative Pulmonary and PEGylation-Based Therapeutic Product Development Drives Business Strategy of Nektar Therapeutics
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Apr 2007
Pro-Pharmaceuticals Announces Tampa General Hospital Dosing Patients with DAVANAT(R)/5-FU in Phase II, First Line, Advanced Biliary Cancer Clinical Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Apr 2007
Survival Data Available From ERBITUX(R) Study in First-Line Treatment of Advanced Head and Neck Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Mar 2007
Roche Submits Application to the FDA for use of XELOX (Xeloda(R) plus oxaliplatin) With or Without Avastin(R) for the Treatment of Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Mar 2007
Amgen Discontinues Vectibix(TM) Treatment in Pacce Trial Evaluating Vectibix(Tm) as Part of Triple Combination Regimen
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Feb 2007
Pro-Pharmaceuticals Submits Orphan Drug Status Application to European Medicines Agency Co-administration of DAVANAT(R) with 5-FU to Treat Cholangiocarcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 23 Feb 2007
Pro-Pharmaceuticals Meeting Scheduled with the FDA
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Feb 2007
Pro-Pharmaceuticals' Begins Process of New Drug Application Submission with the FDA for Co-administration of DAVANAT(R) with 5-FU in Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Feb 2007
ImClone Systems Incorporated and Bristol-Myers Squibb Announce Application In Japan for Use of ERBITUX in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 Jan 2007
NCCN Updates Colon Cancer Guidelines
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Jan 2007
ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Dec 2006
Genetically Modified Cells Attack Tumors
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Nov 2006
Sonus Pharmaceuticals Announces Completion of Patient Enrollment in Phase 3 Pivotal Trial of TOCOSOL(R) Paclitaxel in Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Nov 2006
Pharmion Acquires Cabrellis Pharmaceuticals, Gains Rights to Amrubicin for North America and the European Union
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 6 Nov 2006
Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Oct 2006
Diatos Strengthens Management Team with the Appointment of New Chief Medical Officer and New Chief Sales & Marketing Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Oct 2006
Dako Receives FDA Approval for Use of EGFR pharmDx(TM) With Vectibix(TM)
Diagnostics FDA Oncology

HSMN NewsFeed - 3 Oct 2006
RITA Medical Highlights Recent Clinical Publications Discussing Local Therapy Devices in the Treatment of Liver Tumors Associated With Colorectal Cancer
Devices Oncology

HSMN NewsFeed - 27 Sep 2006
FDA Approves Vectibix(TM) to Treat Patients with Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 Jun 2006
ADVENTRX Presents Encouraging New Supplemental Results for the CoFactor Phase II Metastatic Colorectal Cancer Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Jun 2006
FDA Approves Avastin(R) in Combination With Chemotherapy for Second-Line Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 12 Jun 2006
FDA Grants Priority Review of Panitumumab for Treatment of Patients with Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 May 2006
Sirtex Announces Clinical Trial Evaluating the Use of SIR-Spheres(R) Microspheres with Xeloda(R) for Metastatic Liver Cancer
Devices Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Apr 2006
Pro-Pharmaceuticals Reports Preliminary Data Shows an Objective Partial Tumor Response in Phase II Colorectal Cancer Trial Evaluating DAVANAT(R) with 5-FU
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Apr 2006
Randomized Phase 3 Trial Shows Panitumumab Significantly Improved Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Apr 2006
ImClone Systems Issues Statement Regarding European Commission Approval for ERBITUX(R) for the Treatment of Head and Neck Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Apr 2006
ImClone Systems Announces Receipt of $250 Million Milestone Payment from Bristol-Myers Squibb
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Mar 2006
Amgen and Abgenix Complete Biologics License Application for FDA Approval of Panitumumab
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Mar 2006
Pro-Pharmaceuticals Completes Patient Enrollment in Stage 1 of Phase II Colorectal Cancer Trial Evaluating DAVANAT(R) with 5-FU
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Mar 2006
FDA Approves ERBITUX(R) (Cetuximab) for Treatment of Head and Neck Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Feb 2006
ImClone Systems Issues Statement Regarding Positive Opinion from CHMP for Use of ERBITUX(R) in Head and Neck Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 16 Feb 2006
ImClone Systems Announces Complete Enrollment of Several Studies Examining Potential Survival Benefit Of ERBITUX(R) In Three Major Cancer Types
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Feb 2006
LabCorp(R) Now Offering UGT1A1 Pharmacogenetic Test for Dosing Colorectal Cancer Therapy
Diagnostics Oncology

HSMN NewsFeed - 2 Feb 2006
Pro-Pharmaceuticals Receives 'Compassionate Use' IND for Use of DAVANAT(R)/5-FU to Treat Another Patient with Cholangiocarcinoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Jan 2006
Xanthus Initiates Phase 2 Clinical Trial with Symadex in Patients with Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Jan 2006
Genta Appoints Seasoned Pharma Executive, Lloyd Sanders, as Vice-President for Sales and Marketing
Biopharmaceuticals Oncology Personnel

Return to NewsFeed

Additional items found! 109

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 109 additional stories matching:
Irinotecan
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.